Program
obefazimod
Also written as “ABX464”, “ABX464 50mg” and “Obefazimod 50 mg Capsule”.
Its studies are mostly in Colitis, Ulcerative · Crohn Disease · Arthritis, Rheumatoid · HIV Infections · COVID-19, led by Abivax.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Abivax | 214 open or running | phase 3since Apr 3, 2019 | Apr 10, 2015 | Dec 2026phase 2 · NCT06456593 |
Also a collaborator on its studies: quotient-sciences and Orion Corporation, Orion Pharma.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 7 studies since Apr 10, 2015.
- Nov 29, 2018Phase 2 study in Colitis, UlcerativeNCT03760003 · 355 enrolled · United States, Austria, Belarus and more
- Jan 15, 2019Phase 2 study in Arthritis, RheumatoidNCT03813199 · 60 enrolled · Belgium, Czechia, France and more
- Apr 3, 2019Phase 3 study in Crohn DiseaseNCT03905109 · Belgium
- Jul 5, 2019Phase 2 study in Colitis, UlcerativeNCT04023396 · 217 enrolled · Austria, Belarus, Belgium and more
- Aug 6, 2019Phase 2 study in Arthritis, RheumatoidNCT04049448 · 40 enrolled · Belgium, France, Hungary and more
- May 18, 2020Phase 3 study in COVID-19NCT04393038 · 509 enrolled · Belgium, Brazil, France and more
- Aug 30, 2021Phase 1 study in Healthy VolunteersNCT05032560 · 48 enrolled · Japan
- Oct 11, 2021Phase 1 study in HealthyNCT05121714 · 59 enrolled · United Kingdom
- Dec 15, 2021Phase 2 study in Colitis, UlcerativeNCT05177835 · 203 enrolled · Austria, Belgium, Canada and more
- Aug 17, 20222 phase 3 studies in Colitis, UlcerativeNCT05507216, NCT05507203
- Sep 7, 2022Phase 3 study in Colitis, UlcerativeNCT05535946 · 1,116 enrolled · United States, Argentina, Australia and more
- May 16, 2024Phase 2 study in Crohn DiseaseNCT06456593 · 212 planned · United States, Belgium, Czechia and more
- Feb 25, 2026Phase 1 study in HealthyNCT07453784 · 44 planned · United Kingdom
- Nov 13, 2026Primary completion moved from 2026-09 to 2027-04Date moved laterphase 1 · +7 months · NCT07453784
Ahead
- Dec 2026Primary completion: phase 2 study in Crohn DiseaseNCT06456593
- Apr 2027Primary completion: phase 1 study in HealthyNCT07453784
- Mar 2028Primary completion: phase 2 study in Colitis, UlcerativeNCT05177835
TargetBeta
“Cap binding complex modulator”ChEMBL 37, by rule
Studies
All 21 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07453784Healthy · United Kingdom | 1 | Recruiting | Apr 2027 | 44 |
| NCT06456593Crohn Disease · United States, Belgium, Czechia and more | 2 | Recruiting | Dec 2026 | 212 |
| NCT05535946Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Active, not recruiting | Apr 28, 2026 | 1,116 |
| NCT05507216Colitis, Ulcerative · United States, Argentina, Belgium and more | 3 | Completed | Jun 24, 2025 | 636 |
| NCT05507203Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Completed | Jun 24, 2025 | 639 |
| NCT05177835Colitis, Ulcerative · Austria, Belgium, Canada and more | 2 | Active, not recruiting | Mar 2028 | 203 |
| NCT05121714Healthy · United Kingdom | 1 | Completed | May 18, 2021 | 59 |
| NCT05032560Healthy Volunteers · Japan | 1 | Completed | Feb 18, 2022 | 48 |
| NCT04393038COVID-19 · Belgium, Brazil, France and more | 3 | Terminated | Mar 5, 2021 | 509 |
| NCT04049448Arthritis, Rheumatoid · Belgium, France, Hungary and more | 2 | Completed | Jan 23, 2023 | 40 |
| NCT04023396Colitis, Ulcerative · Austria, Belarus, Belgium and more | 2 | Completed | Feb 23, 2023 | 217 |
| NCT03905109Crohn Disease · Belgium | 3 | Withdrawn | Sep 19, 2022 | 0 |
| NCT03813199Arthritis, Rheumatoid · Belgium, Czechia, France and more | 2 | Completed | Apr 27, 2021 | 60 |
| NCT03760003Colitis, Ulcerative · United States, Austria, Belarus and more | 2 | Completed | Apr 1, 2021 | 355 |
| NCT03368118Colitis, Ulcerative · Belgium | 2 | Completed | Jul 12, 2022 | 22 |
| NCT03093259Colitis, Ulcerative · Austria, Belgium, Czechia and more | 2 | Completed | Jul 25, 2018 | 32 |
| NCT02990325HIV Infections · Spain | 2 | Completed | Dec 27, 2018 | 36 |
| NCT02792686Healthy Volunteers · France | 1 | Completed | Jul 2014 | 24 |
| NCT02735863HIV Infections · Belgium, France, Spain | 2 | Completed | Aug 30, 2017 | 30 |
| NCT02731885Healthy Volunteers · Mauritius | 1 | Completed | Jun 2015 | 48 |
| NCT02452242Human Immunodeficiency Virus Infections · Mauritius, Thailand | 2 | Completed | Dec 2015 | 70 |
How it is read
Names in the registry
- “ABX464”, 15 entries
- “ABX464 50mg”, 3 entries
- “Obefazimod 50 mg Capsule”, 1 entry
- “Obefazimod”, 1 entry
- “ABX464 100 mg”, 1 entry
Conditions, from the studies’ own filings
- Colitis, Ulcerative, 8 studies
- Crohn Disease, 2 studies
- Arthritis, Rheumatoid, 2 studies
- HIV Infections, 2 studies
- COVID-19, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.